Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$3.23 USD
+0.01 (0.31%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $3.24 +0.01 (0.31%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.23 USD
+0.01 (0.31%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $3.24 +0.01 (0.31%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Zacks News
Eiger Completes NDA Submission of Progeria Drug Lonafarnib
by Zacks Equity Research
Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in children.
Xeris Pharmaceuticals, Inc. (XERS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 0.81% and 144.30%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Xeris Pharmaceuticals, Inc. (XERS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Pharmaceuticals, Inc. (XERS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 3.17% and 61.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Xeris Pharmaceuticals, Inc. (XERS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of -31.96% and 57.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.